| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 3,440.8 | 3,076.4 |
| Profit before tax | 783.4 | 1,298.8 |
| Net income | 653.6 | 1,082.9 |
| EPS (diluted, $ a share) | $2.56 | $4.20 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -39.6% |
|---|---|
| Revenue, year on year | +11.8% |
| Operating margin | 20.7% |
10-Q filed with the SEC, NASDAQ: VRTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Vertex Pharmaceuticals Inc: key numbers
- Share price
- $537.79Close, Nov 16
- Market cap
- $136B
- Shares outstanding
- 253.54MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Vertex Pharmaceuticals Inc
All →Vertex Pharmaceuticals EVP, Co & Fo Charles F. Wagner Jr. Sells $8.37M of Stock
Charles F. Wagner Jr., EVP, Co & Fo, sold 15,286 shares of Vertex Pharmaceuticals Inc at $547.87 a share, worth $8.37M in total on Nov 12, 2026. Shares held after the trade: 31,764 (-32.5%).
- Value
- $8.37M
- Shares
- 15,286
- Price
- $547.87
- Role
- EVP, Co & Fo
- Holding change
- -32.5%
- Trade date
- Nov 12, 2026
Vertex Pharmaceuticals CEO & President Reshma Kewalramani Sells $6.31M of Stock
Reshma Kewalramani, CEO & President, sold 11,866 shares of Vertex Pharmaceuticals Inc at $531.53 a share, worth $6.31M in total on Nov 6, 2026. Shares held after the trade: 86,471 (-12.1%).
- Value
- $6.31M
- Shares
- 11,866
- Price
- $531.53
- Role
- CEO & President
- Holding change
- -12.1%
- Trade date
- Nov 6, 2026
Vertex Pharmaceuticals Financial Results
Vertex Pharmaceuticals reported Q3 2026 revenue of $3.44 billion, a 12% increase year-over-year, driven by strong demand for its cystic fibrosis therapies and new product launches. The company raised its full-year 2026 revenue guidance to a range of $13.15 billion to $13.25 billion. During the quarter, Vertex also completed the $9 billion acquisition of Crinetics Pharmaceuticals and secured a $4.5 billion term loan.
“Vertex delivered excellent third quarter results marked by strong revenue growth across the increasingly diversified portfolio, continued advancement of the R&D pipeline, and the successful close of the Crinetics Pharmaceuticals acquisition.”
Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex
“With the potential povetacicept approval in IgAN coming later this month, we are well positioned to establish nephrology as our fifth commercial franchise and expand the reach of our transformative medicines to even more patients.”
Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex
Vertex Pharmaceuticals Leadership Change
Vertex Pharmaceuticals appointed Daniel Brennan to its Board of Directors, effective October 20, 2026, increasing the board size to eleven members. Mr. Brennan, the former CFO of Boston Scientific, will also serve on the Audit and Finance Committee and received an initial $400,000 restricted stock unit award.
- Counterparty
- Daniel Brennan